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comprehensive literature review, with expert panel judgment,
informed the selection of criteria (and their relative weighting)
for the pharmacotherapeutic evaluation. The resultant scoring
system was circulated (in questionnaire format) to prescribers
and stakeholders for comment. Based on statistical analysis of
the latter survey results, the ﬁnal scoring system was developed.
Drug entities which exceeded the evidence threshold score were
entered into a tendering process with pharmaceutical suppliers.
Product lines submitted as a result of the tendering process were
sequentially entered into the second and third phases of the
STEPS process (safety/risk assessment; budget impact analysis).
RESULTS: Three drug entities (from the 5 currently available in
the UK) exceeded the evidence threshold and 29 from 39 sub-
mitted product lines, containing these drug entities, satisﬁed the
safety evaluation/risk assessment criteria. Two product lines,
each containing a different drug entity, were selected for formu-
lary inclusion as a result of the budget impact analysis. The esti-
mated annual cost savings for statins as a result of this selection
process (based on estimated annual usage in Deﬁned Daily
Doses) in this health board, was 40%. CONCLUSION: The
STEPS model has a signiﬁcant contribution to make in contain-
ing statin costs while retaining the most therapeutically appro-
priate agents.
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OBJECTIVES: The purpose of the study is to evaluate the impact
of a tablet splitting program in a large pharmacy beneﬁt man-
agement organization on the costs and utilization of prescription
drugs. METHODS: Using a retrospective cohort study design,
prescription records from January 1, 2005 to June 30, 2005 were
obtained from a pharmacy claims database. Three study cohorts-
voluntary, mandatory, and control cohort were created based on
the enrollment status in the tablet splitting program. The number
of prescriptions dispensed, the total costs and savings per pre-
scription were analyzed and compared for the study drugs
Lexapro, Lipitor, and Zoloft. RESULTS: A total of 606,068 pre-
scriptions, 594,825 in the control, 5226 in the mandatory and
6017 in the voluntary cohort were included. Total cost savings
were obtained by subtracting the difference in cost/days supply
between drugs in the control group and each active treatment
group. Total cost savings are at $179,575.85 and $74,119.53 for
the mandatory and the voluntary cohort respectively after adjust-
ing for the operation costs and subtracting the costs from the
treatment cohorts. An average per prescription cost saving of
$34.36 for the mandatory and $12.31 for the voluntary program
was realized for the three drugs studied. CONCLUSIONS: A
tablet splitting program has been shown to produce signiﬁcant
savings, $34.36 and $12.31 per prescription for the health plan
enrolled in the mandatory and voluntary programs respectively.
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OBJECTIVES: The purpose of this study was to perform a lon-
gitudinal content analysis to assess trends in contributed research
papers presented at ISPOR Annual Meetings and European Con-
gresses from 1998 through 2005 as available in the ISPOR
Research Digest at www.ispor.org, as well as to assess research
quality indicators. METHODS: The database of 5852 con-
tributed presentations at the ISPOR meetings from 1998 through
2005 were analyzed for trends and quality indicators. Trends
were evaluated for outcomes assessed (clinical, economic,
patient-reported outcomes), and types of health policy and dis-
eases studied. Quality indicators were deﬁned as abstracts
including “study perspective, “discounting”, or “ statistical con-
siderations (“conﬁdence interval”, “standard deviation”,
“mean/median”, “sensitivity analysis”). RESULTS: ISPOR held
16 international meetings during 1998–2005. The annual
number of contributed research presentations increased from
270 to 1248 for an eight-year total of 5852 with all topics and
disease categories increasing over time. The major topic areas
covered were cost (42%), patient-reported outcomes including
methods (23%), health policy (23%), methods and concepts
(10%), and clinical outcomes evaluations (6.4%). The top 
four diseases (4992 disease-speciﬁed papers) were neurologi-
cal/mental health (18.5%), cardiovascular (17%), cancer (9%),
and infectious diseases (10%). With respect to quality indicators,
of the abstracts analyzed, a study perspective was mentioned in
18% (37% cost studies, & all others ~4% each); discounting in
8% (16% cost studies & all others <2% each). For statistical
considerations, the percent mentioning mean, median, standard-
deviation, conﬁdence intervals, or sensitivity analysis (12%), was
41%. Overall, the percent of abstracts with these quality indi-
cators generally increased over the study period. CONCLU-
SION: The number of papers has increased over the study period
for multiple topics and diseases. Although the general quality of
papers, as considered in this analysis, was increasing, the percent
of papers that include these quality indicators needs further eval-
uation & improvement.
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OBJECTIVE: The aim of the study to calculate the Lorenz con-
centration curves and Gini coefﬁcient of health expenditures in
Hungary. METHODS: Data derived from the ﬁnancial database
of the Hungarian National Health Insurance Fund Administra-
tion, covering the period 2000–2004. The Hungarian health care
ﬁnancing system based on a regular patient level data reporting
system which allows us to calculate the cumulative frequency dis-
tributions of health expenditures. In each type of care we put the
patients into 100 percentile group ranked by the health expen-
ditures. RESULTS: The top quadrant (top 25%) of the patients
(with highest health expenditures) received different portion of
health expenditures (2004): 72.4% in out-patient care, 64.1%
in in-patient care, 67.3% in chronic care, 56.3% in CT/MRI
examinations, 56.2% in home care, 46.1% in renal dialysis,
83.8% in drug reimbursement, 83.6% in medical devices reim-
bursement. The visual Lorenz curves are presented for each type
of care mentioned earlier and for the ﬁve years between
20000–2004. There was not any signiﬁcant time trend within the
same type of care. We found the following Gini coefﬁcients
(2004): out-patient care: 0.6352, in-patient care: 0.5278, chronic
care: 0.5624, CT/MRI examinations: 0.4459, home care:
0.4319, renal dialysis: 0.4251, drug reimbursement: 0.7444,
medical devices reimbursement: 0.7480. We found signiﬁcant
